When was Lineagen founded?

Lineagen was founded in 2002 and raised its 1st funding round 8 years after it was founded.

Where is Lineagen located?

Lineagen is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah.

How many employees does Lineagen have?

As of Sep 30, 2026, the latest employee count at Lineagen is 16.

Is Lineagen a funded company?

Lineagen is a funded company, having raised a total of $66.9M across 7 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Jun 22, 2010.

When was the latest funding round of Lineagen?

Lineagen's latest funding was a $***** Series C round on Jan 26, 2015, with participation from 3 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.65B in funding in 2026 to date.

Where does Lineagen rank among its competitors?

Lineagen ranks 19th amongst 93 active competitors, of which 23 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was MARAbio, which secured $19.1M in Sep, 2024.

Who are the top competitors of Lineagen?

Lineagen's top competitors include Fulgent Genetics, Myriad Genetics and Invitae. Among them, MARAbio secured the most recent funding round in September, 2024.

Lineagen - 2026 Company Profile, Funding & Competitors

Company Details

Lineagen helps physicians to evaluate children with autism or other forms of developmental delay. It offers sequencing-based diagnostic tests and consultative services for autism & developmental disorders for parents. It also provides digital platforms m-chat.org, an online screening tool and OpenAutism.com for information flow between specialists.

Website: lineagen.com
Registered Address: Salt Lake City, Utah

Key Metrics

Founded Year

2002

Location

Salt Lake City, United States

Stage

Acquired

Total Funding

$66.9M in 7 rounds

Latest Funding Round

Series C, Jan 26, 2015, $*****

Investors

Sanderling Ventures & 11 more

Ranked

19^th among 93 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

Fulgent Genetics & 112 more

Exit Details

Acquired by Bionano Genomics (Aug 24, 2020)

View Lineagen's full profile

Lineagen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
LINEAGEN INC CIN: 204508128 , United States, Active	Dec 31, 1999	-	40 (As on Dec 31, 2020)	-

Lineagen got acquired by Bionano Genomics on Aug 24, 2020.

Click here to take a look at Lineagen's acquisition in detail

Lineagen has raised a total funding of $66.9M over 7 rounds. Its first funding round was on Jun 22, 2010. Its latest funding round was a Series C round on Jan 26, 2015 for $*****. 3 investors participated in its latest round. Lineagen has 12 institutional investors.

Here is the list of recent funding rounds of Lineagen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2015	1467981	Series C	3514739	2078195	3857320	9700024
Nov 25, 2013	3633506	Series C	3815099	1893666	5936471	Sanderling Ventures & 7 more
Nov 09, 2013	7147299	Series B	1464971	9936104	4149043	Sanderling Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Lineagen's funding rounds and investors

Lineagen's employee count trend

Lineagen has 16 employees as of Sep 26. Here is Lineagen's employee count trend over the years:

Uncover Lineagen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lineagen include Fulgent Genetics, Myriad Genetics and Invitae. Here is the list of Top 10 competitors of Lineagen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Fulgent Genetics 2011, Temple City (United States), Acquired	Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer	$34.8M	-	70/100
2nd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	66/100
3rd	Invitae 2010, San Francisco (United States), Public	Provider of home-based genetic test for individuals	$190M	Perceptive Advisors, Rock Springs Capital ... & 22 others	64/100
4th	Celmatix 2009, New York City (United States), Series C	Pioneering ovarian health therapeutics for women's unique biological needs	$24.9M	Topspin Consumer Partners, Partnership for New York City ... & 4 others	56/100
5th	Linus Biotechnology 2020, New York City (United States), Series A	Developer of diagnostic tests for central nervous system and gastrointestinal disorders	$47.6M	GreatPoint Ventures, Bow Capital & 3 others	55/100
6th	Genome Medical 2016, Monterey (United States), Series D	Provider of clinical and DTC genomic testing services	$173M	Samsung Catalyst Fund, Canaan & 21 others	54/100
7th	MARAbio 2016, Salt Lake City (United States), Series A	Developer of blood test for detecting maternal autoantibody-related autism	$19.1M	MAK Capital, Moai Capital	50/100
8th	Centogene 2006, Rostock (Germany), Public	Provider of biochemical/genetic tests to detect mutations and rare diseases	$28M	TVM Capital, Deutsche Private Equity & 2 others	50/100
9th	AnchorDx 2015, Guangzhou (China), Series C	Developer of high throughput gene sequencing platform for clinical application	$73M	Orbimed, Frontline BioVentures & 5 others	48/100
10th	Blueprint Genetics 2012, Espoo (Finland), Acquired	Provider of genetic diagnostics and clinical interpretation for hereditary diseases	$26.2M	Inventure, MTIP & 4 others	48/100
19th	Lineagen 2002, Salt Lake City (United States), Acquired	Sequencing-based diagnostic test and consultative services for autism	$66.9M	Health Quest Capital, Hatteras Funds & 10 others	43/100